In clinical practice, PCa is confirmed or excluded by transrectal ultrasound-targeted biopsy, based on the results of digital rectal examination or serum prostate-specific antigen (PSA) levels4, and perfusion analysis by CETRUS5. The gene discussed is KLK3; the disease is posterior cortical atrophy.